How can we, humans, look at our relationship to nature differently? In season three of Going Wild, on top of stories about animals, we invite you to journey through the entire ecological web — from the tiniest of life forms to apex predators — alongside the scientists, activists and adventurers who study it. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals in their natural habitats all over the world for years. Our award-winning podcast takes you inside the hidde ...
…
continue reading
İçerik Sano Genetics tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Sano Genetics veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Player FM - Podcast Uygulaması
Player FM uygulamasıyla çevrimdışı Player FM !
Player FM uygulamasıyla çevrimdışı Player FM !
EP105: Warren Huff, CEO and Chairman of Reata Pharmaceuticals, shares perspectives on provocative biology and the development of treatments for rare diseases
MP3•Bölüm sayfası
Manage episode 375003943 series 2631947
İçerik Sano Genetics tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Sano Genetics veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
In this episode, Patrick welcomes J. Warren Huff, CEO and Chairman of Reata Pharmaceuticals. Reata is known for innovating small-molecule therapies for severe and life-threatening diseases. Listen in as Warren walks us through their approach of partnering with Universities to find scientific discoveries that could become the next generation of therapies, and Reata’s recent success developing a groundbreaking new treatment for Friedreich’s Ataxia (FA), thanks to close collaboration with patient organizations and novel use of natural history data to accelerate their clinical development. 0:00 The beginnings of Reata 2:40 Partnering with universities for breakthroughs in research 5:30 Implications of cancer prevention research on chronic diseases 11:40 Potential concerns in medical ethics and Big Pharma when developing groundbreaking treatments 13:20 Research on NRF2 and its role in treating Friedreich’s Ataxia, a genetic mitochondrial disease that leads to motor neuron decline 18:00 What is a natural history study, and how was it used in Reata’s FA clinical development? 22:50 The potential for clinical grade wearable devices 23:35 Determining clinical endpoints in clinical trials 26:00 The FDA’s approval process for rare disease treatments 32:40 Potential for expanding newborn screening programs 36:00 The generalizability of NRF2-based research to other inflammatory diseases and diseases related to mitochondrial malfunction 39:40 What is Type 3 Diabetes? 40:30 Warren’s career start as a lawyer and his journey to biotech 43:00 Searching for provocative biology 46:20 Major targets for the HSP program 48:30 Closing remarks and lessons in resiliency
…
continue reading
182 bölüm
MP3•Bölüm sayfası
Manage episode 375003943 series 2631947
İçerik Sano Genetics tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Sano Genetics veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
In this episode, Patrick welcomes J. Warren Huff, CEO and Chairman of Reata Pharmaceuticals. Reata is known for innovating small-molecule therapies for severe and life-threatening diseases. Listen in as Warren walks us through their approach of partnering with Universities to find scientific discoveries that could become the next generation of therapies, and Reata’s recent success developing a groundbreaking new treatment for Friedreich’s Ataxia (FA), thanks to close collaboration with patient organizations and novel use of natural history data to accelerate their clinical development. 0:00 The beginnings of Reata 2:40 Partnering with universities for breakthroughs in research 5:30 Implications of cancer prevention research on chronic diseases 11:40 Potential concerns in medical ethics and Big Pharma when developing groundbreaking treatments 13:20 Research on NRF2 and its role in treating Friedreich’s Ataxia, a genetic mitochondrial disease that leads to motor neuron decline 18:00 What is a natural history study, and how was it used in Reata’s FA clinical development? 22:50 The potential for clinical grade wearable devices 23:35 Determining clinical endpoints in clinical trials 26:00 The FDA’s approval process for rare disease treatments 32:40 Potential for expanding newborn screening programs 36:00 The generalizability of NRF2-based research to other inflammatory diseases and diseases related to mitochondrial malfunction 39:40 What is Type 3 Diabetes? 40:30 Warren’s career start as a lawyer and his journey to biotech 43:00 Searching for provocative biology 46:20 Major targets for the HSP program 48:30 Closing remarks and lessons in resiliency
…
continue reading
182 bölüm
همه قسمت ها
×Player FM'e Hoş Geldiniz!
Player FM şu anda sizin için internetteki yüksek kalitedeki podcast'leri arıyor. En iyi podcast uygulaması ve Android, iPhone ve internet üzerinde çalışıyor. Aboneliklerinizi cihazlar arasında eş zamanlamak için üye olun.